Elanco Animal Health Incorporated announced on November 15, 2024, the acquisition of a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom.
This acquisition is crucial for Elanco as the Speke facility produces several farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily outside the U.S. Elanco previously held a long-term supply agreement with TriRx Speke Ltd.
Elanco paid $25 million in cash at closing to acquire the facility and related assets, assuming site ownership immediately. The company continues to expect an adjusted EBITDA headwind related to this situation between $25 million and $35 million in 2025, primarily impacting gross profit.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.